Switch theme
Sign up to access all valuation multiples
Tibet Cheezheng Tibetan Medicine Co Ltd is Tibetan medicine manufacturer. It is mainly engaged in the research, development, production, and sales of Tibetan medicines. The company's products include medicines such as emplastrum, ointments, granules, pills, and powders.
1997
1.2K+
LTM Revenue n/a
LTM EBITDA n/a
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cheezheng Tibetan Medicine has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cheezheng Tibetan Medicine achieved revenue of $282M and an EBITDA of $110M.
Cheezheng Tibetan Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cheezheng Tibetan Medicine valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $282M | n/a | XXX | XXX | XXX |
| Gross Profit | $207M | $237M | XXX | XXX | XXX |
| Gross Margin | 74% | NaN% | XXX | XXX | XXX |
| EBITDA | $110M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 39% | NaN% | XXX | XXX | XXX |
| Net Profit | $98.6M | $65.1M | XXX | XXX | XXX |
| Net Margin | 35% | NaN% | XXX | XXX | XXX |
| Net Debt | $92.5M | $164M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cheezheng Tibetan Medicine's stock price is CNY 24 (or $3).
Cheezheng Tibetan Medicine has current market cap of CNY 12.8B (or $1.8B), and EV of CNY 11.3B (or $1.6B).
See Cheezheng Tibetan Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cheezheng Tibetan Medicine has market cap of $1.8B and EV of $1.6B.
Cheezheng Tibetan Medicine's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cheezheng Tibetan Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cheezheng Tibetan Medicine and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCheezheng Tibetan Medicine's NTM/LTM revenue growth is n/a
Cheezheng Tibetan Medicine's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Cheezheng Tibetan Medicine's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cheezheng Tibetan Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cheezheng Tibetan Medicine and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cheezheng Tibetan Medicine acquired XXX companies to date.
Last acquisition by Cheezheng Tibetan Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Cheezheng Tibetan Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cheezheng Tibetan Medicine founded? | Cheezheng Tibetan Medicine was founded in 1997. |
| Where is Cheezheng Tibetan Medicine headquartered? | Cheezheng Tibetan Medicine is headquartered in China. |
| How many employees does Cheezheng Tibetan Medicine have? | As of today, Cheezheng Tibetan Medicine has 1.2K+ employees. |
| Is Cheezheng Tibetan Medicine publicy listed? | Yes, Cheezheng Tibetan Medicine is a public company listed on SHE. |
| What is the stock symbol of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine trades under 002287 ticker. |
| When did Cheezheng Tibetan Medicine go public? | Cheezheng Tibetan Medicine went public in 2009. |
| Who are competitors of Cheezheng Tibetan Medicine? | Similar companies to Cheezheng Tibetan Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine's current market cap is $1.8B |
| Is Cheezheng Tibetan Medicine profitable? | Yes, Cheezheng Tibetan Medicine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
